Document is current
Any future updates will be listed below
-
Authors
Lefley, Diane
Howard, Faith
Arshad, Fawaz
Bradbury, Steven
Brown, Hannah
Tulotta, Claudia
Eyre, Rachel
Alférez, Denis
Wilkinson, J. Mark
Holen, Ingunn
Clarke, Robert B.
Ottewell, Penelope https://orcid.org/0000-0002-4826-0771
-
Funding
Funding for this research was provided by:
Medical Research Council UK (MR/POOOO96/1)
International Bone and Mineral Society (N/A)
Breast Cancer Now (2016MaySP763, MAN-Q2)
Weston Park Cancer Charity (CA)
- License Information
-
More Information
Article History
Received: 11 July 2019
Accepted: 25 October 2019
First Online: 29 November 2019
Ethics approval and consent to participate
: Human bone samples were collected under HTA licence 12182, Sheffield Musculoskeletal Biobank, University of Sheffield, UK. All patients’ tumours used to develop PDX provided fully informed consent in accordance with local research ethics committee guidelines. Ethical approval for metastatic samples was granted by the Central Office for Research Ethics Committee study number 05/Q1402/25. Early breast cancer samples were collected via the Manchester Cancer Research Centre Biobank which is licenced by the Human Tissue Authority (licence number: 30,004) and has been ethically approved as a research tissue bank by the South Manchester Research Ethics Committee (Ref: 07/H1003/161 + 5). All patients provided written, informed consent prior to participation in this study in accordance with the World Medical Association Declaration of Helsinki.
: All authors consent to publication of the above manuscript and sharing of raw data and materials.
: The authors declare that they have no competing interests.
